The continued solid uptake of BD's products is expected to have driven fiscal second-quarter revenues despite transitory ...

Besides Wall Street's top -and-bottom-line estimates for Becton Dickinson (BDX), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared ...

Becton, Dickinson and Company has struggled over the past decade, with a 10-year CAGR of only 5.1%. Read what keeps me on the ...

Hologic HOLX is set to release second-quarter fiscal 2025 results on May 1, after the closing bell. The Zacks Consensus ...

Shares of Becton Dickinson & Co. BDX advanced 1.05% to $204.45 Thursday, on what proved to be an all-around positive trading ...

BP is not Elliott’s only current campaign in the oil fields. In the spring of 2024, Elliott revealed a $1 billion stake in ...

Detailed price information for Century Therapeutics Inc (IPSC-Q) from The Globe and Mail including charting and trades.

Shares of Becton Dickinson & Co. BDX rose 1.22% to $202.32 Wednesday, on what proved to be an all-around favorable trading ...

Piper Sandler analyst Jason Bednar lowered the firm’s price target on Becton Dickinson to $260 from $280 and keeps an Overweight rating on the ...

BD (NYSE: BDX) announced today that it received FDA 510(k) clearance for its Phasix ST umbilical hernia patch.

Piper Sandler analyst Jason Bednar maintained a Buy rating on Becton Dickinson (BDX – Research Report) today and set a price target of $260.00.

Former Edwards Lifesciences Critical Care Unit, renamed BD Advanced Patient Monitoring, yesterday launched the HemoSphere ...